NasdaqCM - Delayed Quote USD

Atossa Therapeutics, Inc. (ATOS)

1.5400 +0.0800 (+5.48%)
At close: May 14 at 4:00 PM EDT
1.5992 +0.06 (+3.84%)
Pre-Market: 8:43 AM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Steven C. Quay FCAP, M.D., Ph.D. Chairman, CEO & President 1.21M -- 1951
Ms. Heather Rees CPA Senior VP of Finance & Principal Accounting Officer 520.64k -- 1973
Ms. Delly Behen P.H.R. Senior Vice President of Administration & HR -- -- --
Mr. Eric Van Zanten Vice President of Investor & Public Relations -- -- --
Dr. Richard Graydon M.D., Ph.D. Interim Chief Medical Officer -- -- --

Atossa Therapeutics, Inc.

107 Spring Street
Seattle, WA 98104
United States
206 588 0256 https://www.atossatherapeutics.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
12

Description

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

Corporate Governance

Atossa Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

  • May 14, 2024
    DEL AM: Separately filed delaying amendment under Securities Act Rule 473 to delay effectiveness of a 1933 Act registration statement
    See Full Filing
  • May 13, 2024
    10-Q: Periodic Financial Reports
    See Full Filing
  • Apr 02, 2024
    8-K/A: Corporate Changes & Voting Matters
    See Full Filing
  • Apr 01, 2024
    10-K: Periodic Financial Reports
    See Full Filing
  • Mar 18, 2024
    8-K: Corporate Changes & Voting Matters
    See Full Filing

Upcoming Events

Aug 12, 2024 - Aug 16, 2024
Atossa Therapeutics, Inc. Earnings Call

Related Tickers

OCGN Ocugen, Inc.
1.7000
-6.08%
 
TNXP Tonix Pharmaceuticals Holding Corp.
0.1800
+5.20%
 
SLS SELLAS Life Sciences Group, Inc.
1.3700
0.00%
 
CTXR Citius Pharmaceuticals, Inc.
0.6876
-1.11%
 
JAGX Jaguar Health, Inc.
0.2749
-5.30%
 
VXRT Vaxart, Inc.
0.8647
+5.45%
 
AKBA Akebia Therapeutics, Inc.
1.2300
-4.65%
 
CADL Candel Therapeutics, Inc.
10.70
+4.90%
 
RVPH Reviva Pharmaceuticals Holdings, Inc.
1.8250
+7.35%
 
INO Inovio Pharmaceuticals, Inc.
11.42
+0.53%